FDA Clears Broad Spectrum Cephalosporin Antibiotic For Adults And Children
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Clears Broad Spectrum Cephalosporin Antibiotic For Adults And Children

MORRIS PLAINS, NJ -- December 8, 1997 -- The United States Food and Drug Administration (FDA) has granted marketing clearance to Warner-Lambert Co.’s Omnicef(R) (cefdinir), a broad spectrum cephalosporin antibiotic for adult and pediatric use.

In an extensive controlled clinical trial program involving over 13,000 patients (9,600 adults and 3,400 children) over a four-year period, Omnicef (cefdinir) capsules and Omnicef (cefdinir) powder for oral suspension have proven to be effective, well-tolerated therapies for a wide variety of community infections.

In adults and adolescents, Omnicef is indicated for the treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, acute bacterial sinusitis (sinus infections), pharyngitis and tonsillitis caused by Streptococcus pyogenes (strep throat) and uncomplicated skin and skin structure infections. In children, Omnicef is indicated for the treatment of acute bacterial otitis, media (middle ear infections), acute bacterial sinusitis, pharyngitis and tonsillitis caused by Streptococcus pyogenes and uncomplicated skin and skin structure infections.

The adult formulation of Omnicef is a 300 milligram capsule. The pediatric formulation is a strawberry-flavored suspension.

Dosing is flexible and Omnicef can be taken without regard to meals. In adults and adolescents, physicians may direct patients to take two 300 mg. capsules once daily or one 300 mg, capsule twice daily for most infections. The pediatric dosing regimen, in most instances, is also either once daily (14 milligram per kilogram of the child's weight) or twice daily (two doses of 7 mg./kg.). Omnicef is dosed twice daily for pneumonia and skin infections.

Omnicef has proven to be well tolerated in clinical trials. Most side effects involved the gastrointestinal tract. Omnicef should not be used in patients with a known allergy to the cephalosporin class of antibiotics.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities